Grifols (GRFS) Competitors $7.44 -0.08 (-1.13%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GRFS vs. TEVA, SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, SRPT, and QGENShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Grifols vs. Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Intra-Cellular Therapies Viatris Moderna Dr. Reddy's Laboratories Vaxcyte Sarepta Therapeutics Qiagen Teva Pharmaceutical Industries (NYSE:TEVA) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk. Which has higher earnings and valuation, TEVA or GRFS? Grifols has lower revenue, but higher earnings than Teva Pharmaceutical Industries. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.15-$1.64B-$1.45-11.62Grifols$7.13B0.72$64.20MN/AN/A Does the media favor TEVA or GRFS? In the previous week, Teva Pharmaceutical Industries had 17 more articles in the media than Grifols. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 4 mentions for Grifols. Teva Pharmaceutical Industries' average media sentiment score of 0.88 beat Grifols' score of 0.27 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 12 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is TEVA or GRFS more profitable? Grifols has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Grifols' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-9.91% 42.46% 6.65% Grifols N/A N/A N/A Do analysts recommend TEVA or GRFS? Teva Pharmaceutical Industries presently has a consensus price target of $23.57, suggesting a potential upside of 39.95%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, equities research analysts plainly believe Teva Pharmaceutical Industries is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Grifols 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Does the MarketBeat Community believe in TEVA or GRFS? Teva Pharmaceutical Industries received 981 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 67.87% of users gave Teva Pharmaceutical Industries an outperform vote while only 56.09% of users gave Grifols an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes133167.87% Underperform Votes63032.13% GrifolsOutperform Votes35056.09% Underperform Votes27443.91% Do institutionals & insiders believe in TEVA or GRFS? 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, TEVA or GRFS? Teva Pharmaceutical Industries has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. SummaryTeva Pharmaceutical Industries beats Grifols on 14 of the 17 factors compared between the two stocks. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.16B$7.05B$5.81B$9.13BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A5.9925.9319.18Price / Sales0.72324.61463.3381.20Price / Cash9.3567.8344.0437.47Price / Book0.606.827.714.77Net Income$64.20M$138.11M$3.18B$245.80M7 Day Performance2.53%-0.60%-0.52%-0.80%1 Month Performance2.11%-0.08%1.71%-0.44%1 Year Performance-14.23%-2.10%18.52%16.44% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols2.1748 of 5 stars$7.44-1.2%N/A-11.8%$5.12B$7.13B0.0023,737TEVATeva Pharmaceutical Industries2.9342 of 5 stars$16.24-2.4%$23.57+45.2%+30.1%$18.39B$16.54B-11.2037,851SMMTSummit Therapeutics2.3161 of 5 stars$21.37-2.1%$33.57+57.1%+516.6%$15.76B$700,000.00-76.32110Gap UpGMABGenmab A/S4.6083 of 5 stars$21.30+1.8%$42.17+98.0%-22.5%$14.10B$2.39B20.682,204ITCIIntra-Cellular Therapies3.9604 of 5 stars$127.82-0.2%$103.62-18.9%+74.4%$13.59B$464.37M-146.92560Earnings ReportAnalyst ForecastNews CoverageVTRSViatris2.3367 of 5 stars$10.80flat$13.67+26.5%-16.5%$12.89B$15.43B-14.5938,000News CoverageMRNAModerna4.7566 of 5 stars$32.99+3.4%$66.89+102.8%-61.2%$12.70B$6.85B-5.675,600Analyst DowngradeOptions VolumeHigh Trading VolumeRDYDr. Reddy's Laboratories2.8963 of 5 stars$13.60-2.8%$17.00+25.0%-11.7%$11.35B$311.31B21.6527,048Gap DownPCVXVaxcyte2.6035 of 5 stars$84.00+0.2%$127.71+52.0%+11.3%$10.47BN/A-18.26160Insider TradePositive NewsSRPTSarepta Therapeutics4.5135 of 5 stars$107.95-1.4%$176.77+63.8%-20.4%$10.31B$1.24B86.361,314Upcoming EarningsQGENQiagen4.4462 of 5 stars$39.85-0.5%$48.78+22.4%-7.3%$8.84B$1.98B110.975,967Analyst Downgrade Related Companies and Tools Related Companies TEVA Alternatives SMMT Alternatives GMAB Alternatives ITCI Alternatives VTRS Alternatives MRNA Alternatives RDY Alternatives PCVX Alternatives SRPT Alternatives QGEN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRFS) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
